CPM

By Targets:	Apoptosis (4) Biochemical Assay Reagents (1) Fluorescent Dye (1) Isotope-Labeled Compounds (1) NF-κB (3) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cancer (2) Inflammation/Immunology (3) Neurological Disease (1)

Cat. No.	Nom du produit	Target	Áreas de investigación	Chemical Structure

HY-D0069

CPM

Fluorescent Dye Others

CPM is a maleimide derivative, acting as a blue fluorescent thiol-reactive dye. The excitation/emission maxima is 384/470 nm .

*CPM*	Fluorescent Dye	Others
CPM is a maleimide derivative, acting as a blue fluorescent thiol-reactive dye. The excitation/emission maxima is 384/470 nm .

HY-13010

Laquinimod 2 Publications Verification ABR-215062	NF-κB Apoptosis	Inflammation/Immunology
Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-P10057

cpm-1285	Apoptosis	Cancer
cpm-1285 induces apoptosis by functionally blocking intracellular Bcl-2 and related death antagonists. cpm-1285 shows strong binding potency to Bcl-2 with an IC₅₀ value of 130 nM. cpm-1285 reduces tumor burden in mice .

HY-P10058

cpm-1285m	Biochemical Assay Reagents	Cancer
cpm-1285m is a cell-permeable mutated peptide analogue of cpm-1285 (Bcl-2 inhibitory peptide). cpm-1285m contains a single substitution of alanine for Leu-151, and exhibits a decrease in Bcl-2 binding affinity with a reduction in IC₅₀ of ∼15-fold. cpm-1285m can be used as a control of cpm-1285 .

HY-RS03100

CPM Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CPM Human Pre-designed siRNA Set A contains three designed siRNAs for CPM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CPM Human Pre-designed siRNA Set A CPM Human Pre-designed siRNA Set A

HY-W062904

Laquinimod sodium ABR-215062 sodium	NF-κB Apoptosis	Neurological Disease Inflammation/Immunology
Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-13010S

Laquinimod-d5 ABR-215062-d₅	Isotope-Labeled Compounds Apoptosis NF-κB	Inflammation/Immunology
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

Cat. No.	Nom du produit	Type

HY-D0069

CPM

Fluorescent Dyes/Probes

CPM is a maleimide derivative, acting as a blue fluorescent thiol-reactive dye. The excitation/emission maxima is 384/470 nm .

*CPM*	Fluorescent Dyes/Probes
CPM is a maleimide derivative, acting as a blue fluorescent thiol-reactive dye. The excitation/emission maxima is 384/470 nm .

Cat. No.	Nom du produit	Target	Research Area

HY-P10057

cpm-1285	Apoptosis	Cancer
cpm-1285 induces apoptosis by functionally blocking intracellular Bcl-2 and related death antagonists. cpm-1285 shows strong binding potency to Bcl-2 with an IC₅₀ value of 130 nM. cpm-1285 reduces tumor burden in mice .

HY-P10058

cpm-1285m	Biochemical Assay Reagents	Cancer
cpm-1285m is a cell-permeable mutated peptide analogue of cpm-1285 (Bcl-2 inhibitory peptide). cpm-1285m contains a single substitution of alanine for Leu-151, and exhibits a decrease in Bcl-2 binding affinity with a reduction in IC₅₀ of ∼15-fold. cpm-1285m can be used as a control of cpm-1285 .

Species:	Human (1) Mouse (1)
Tag:	His (2)
Source:	HEK293 (2)

Cat. No.	Compare	Nom du produit	Species	Source

HY-P7737

	*Carboxypeptidase M/CPM* Protein, Human (HEK293, His)** rHuCarboxypeptidase M, His; Carboxypeptidase M; CPM	Human	HEK293
	Carboxypeptidase M Protein, Human (HEK293, His) is an approximately 55.0 kDa Carboxypeptidase M protein with a His-flag. Carboxypeptidase M is a membrane-bound arginine/lysine carboxypeptidase enzyme belongs to the carboxypeptidases family.

HY-P7738

	*Carboxypeptidase M/CPM* Protein, Mouse (406a.a, HEK293, His)** rMuCarboxypeptidase M, His; Carboxypeptidase M; CPM	Mouse	HEK293
	Carboxypeptidase M Protein, Mouse (HEK293, His) is an approximately 56.0 kDa mouse carboxypeptidase M protein with a His-flag. Carboxypeptidase M is a membrane-bound arginine/lysine carboxypeptidase enzyme belongs to the carboxypeptidases family.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Nom du produit	Chemical Structure

HY-13010S

Laquinimod-d5
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

Laquinimod-d5

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Nom du demandeur *			Nom de l'organisation *
Department *
Adresse électronique *			Nom du produit *
Cat. No.			Requested quantity *
Numéro de téléphone *
Remarks

Inhibitors & Agonists

Fluorescent Dye

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.